CB-03-01 Investor update

[burtandernie]

It always has a chance if it works well with minimal sides. The AA route isnt going to go away if setipiprant comes out it will simply be another option and angle of attack. We are kidding ourselves if we think everyone will tolerate setipiprant or CB. They could give out placebos and this forum would be full of people complaining about their sex drive or whatever random thing they noticed that day out of the ordinary. Some people will have issues with treatments and need other options instead so the more the better.

[FearTheLoss]

Well, if they plan on releasing this around the time setipiprant is released, they don't have a chance.

I sincerely hope you're right. However, I just hope one of them gets released at all.

[It's2014ComeOnAlready]

No, it finishes November 2015. We probably won't see that data for a couple months to a year after.

Well, if they plan on releasing this around the time setipiprant is released, they don't have a chance.

[FearTheLoss]

The phase 2 POC trial data collection etc finishes at the end of this month. Keep an eye out!

No, it finishes November 2015. We probably won't see that data for a couple months to a year after.

[It's2014ComeOnAlready]

The phase 2 POC trial data collection etc finishes at the end of this month. Keep an eye out!

[Tenma]

Not sure if I buy that - if Cosmo have contracted Salix to run the trials, this will be run out of different dept to drug development...clinical trials as a managed service are a nice income earner for any drug company - you dont bin those... fair margins and good revenue

Salix has nothing to do with CB.

Intrepid Therapeutics is running the USA trial.

Still, for us i think good news Cosmo didnt merge with Salix few months ago.

[charlie76761]

CB will probably get shelved. Salix, who are running the trials in the US, was just bought out by Valeant. Valeant has a long history of buying up companies and shelving the drugs they have in development.

http://www.reuters.com/article/2015/...0LQ0V420150223

Not sure if I buy that - if Cosmo have contracted Salix to run the trials, this will be run out of different dept to drug development...clinical trials as a managed service are a nice income earner for any drug company - you dont bin those... fair margins and good revenue

[Gerhard]

CB will probably get shelved. Salix, who are running the trials in the US, was just bought out by Valeant. Valeant has a long history of buying up companies and shelving the drugs they have in development.

http://www.reuters.com/article/2015/...0LQ0V420150223

I thought Valeant was supporting Cosmo's trailing of this product? They seemed to have good hope for it. Cosmo was working with Valeant on CB-03-01 just last year I believe.

[It's2014ComeOnAlready]

CB will probably get shelved. Salix, who are running the trials in the US, was just bought out by Valeant. Valeant has a long history of buying up companies and shelving the drugs they have in development.

http://www.reuters.com/article/2015/02/23/us-valeantpharms-salixpharms-idUSKBN0LQ0V420150223

[Gerhard]

Maybe but your basically guessing. I dont think any of the past small studies they have done nor people buying chemicals from unlicensed manufacturers and experimenting on their own is actually a good representation of the effectiveness of the actual final product or chemical. The better safety profile is one of the biggest advantages to it even if its no better than fin.

Agreeing entirely with this. We all extoll the virtues of a fin with no side effects and CB could be that. Honestly, I hope that all of these treatments come to fruition.

[burtandernie]

I don't think there's any point to CB. The PGD2 blockers will be more useful for maintenance, and things like SM or BIM seem much more promising re-growth wise. I doubt the side effect profile for CB is too bad, but I also don't think it'll be all that useful.

Maybe but your basically guessing. I dont think any of the past small studies they have done nor people buying chemicals from unlicensed manufacturers and experimenting on their own is actually a good representation of the effectiveness of the actual final product or chemical. The better safety profile is one of the biggest advantages to it even if its no better than fin.

[KO1]

Why do they need FDA approval? This is an italian firm.....they could release it in any country right?

[sdsurfin]

I don't think there's any point to CB. The PGD2 blockers will be more useful for maintenance, and things like SM or BIM seem much more promising re-growth wise. I doubt the side effect profile for CB is too bad, but I also don't think it'll be all that useful.

[FearTheLoss]

BID 1% is not the vehicle. BID means bis in diem which is Latin for twice a day. It's standard pharma terminology.

So they are applying 1% CB twice a day.

Re: CB's strength, it doesn't really matter that CB is a slightly weaker AA than others. That just means you may need a higher concentration. The important thing is what happens when it penetrates the skin ie it supposedly quickly degrades to an inactive form. Unlike say flutamide which is a very strong AA but has systemic effects.

I don't recall Cosmo ever saying CB causes massive new hair growth. The pilot study showed an increase in hair count but that doesn't mean new hairs, it just means more hairs in anagen, which means more hairs at any given time. It won't cause much new growth anyway. AAs do not grow new hair. They don't even really reverse miniaturisation except in very early or very rare cases. It should significantly outperform Propecia though, because Propecia only lowers scalp DHT by about 30%. CB should beat that comfortably, and block T as well as DHT.

The best way to think of CB is basically the same as RU but more stable. And also quality control assured of it gets released officially.

I highly doubt cb wil ever be released. All AA's will cause side effects. I hope I'm wrong, but I believe that's the truth.

[Pate]

Not much to say, they expect to finish Phase 3 for acne with CB-03-01 by the end of 2017. And it shows great promise without serious side effects. The vehicle is BID 1% (don't know what this is).

For alopecia they are taking NW2 - NW5s, mostly NW3 and NW3 vertex to see the results of CB vs. placebo and minox. Phase 2 should finish by the end of this year.

BID 1% is not the vehicle. BID means bis in diem which is Latin for twice a day. It's standard pharma terminology.

So they are applying 1% CB twice a day.

Re: CB's strength, it doesn't really matter that CB is a slightly weaker AA than others. That just means you may need a higher concentration. The important thing is what happens when it penetrates the skin ie it supposedly quickly degrades to an inactive form. Unlike say flutamide which is a very strong AA but has systemic effects.

I don't recall Cosmo ever saying CB causes massive new hair growth. The pilot study showed an increase in hair count but that doesn't mean new hairs, it just means more hairs in anagen, which means more hairs at any given time. It won't cause much new growth anyway. AAs do not grow new hair. They don't even really reverse miniaturisation except in very early or very rare cases. It should significantly outperform Propecia though, because Propecia only lowers scalp DHT by about 30%. CB should beat that comfortably, and block T as well as DHT.

The best way to think of CB is basically the same as RU but more stable. And also quality control assured of it gets released officially.